TREA

97523882 - O VIVANI

Follow

Information

  • Trademark
  • 97523882
  • Serial Number
    97523882
  • Filing Date
    July 28, 2022
    a year ago
  • Transaction Date
    February 22, 2024
    4 months ago
  • Status Date
    February 07, 2024
    4 months ago
  • Published for Opposition Date
    June 20, 2023
    a year ago
  • Location Date
    August 15, 2023
    10 months ago
  • Status Code
    730
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    GRYGIEL, JONATHAN C
  • Attorney Docket Number
    S-17
    Attorney Name
    Scott B. Dunbar
    Law Office Assigned Location Code
    N20
  • Owners
Information
Mark Drawing Code
3000
Mark Identification
O VIVANI
Case File Statements
  • DM0000: The mark consists of the wording "Vivani" with an arch of spheres with a stylized O at the top, where the arch of spheres start at the dot of the first "i" in "Vivani" and ends at the dot of the second "i" in "Vivani", all in aqua green.
  • GS0051: Implantable drug delivery devices having a drug reservoir filled with pharmaceutical preparations and a nanoporous membrane for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy; Implantable drug delivery devices having a drug reservoir and a nanoporous membrane sold preloaded with a therapeutic agent, namely, an injectable device for time release of the therapeutic agent for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy
  • CC0000: The color(s) aqua green is/are claimed as a feature of the mark.
  • GS0011: Nanoporous membranes used in drug delivery devices for controlling the rate of release of the subject therapeutic compound by selecting nano-pores slightly larger than the molecular diameter of the therapeutic compound; Nanoporous membranes used for controlling the rate of release of the subject therapeutic compound by selecting nano-pores slightly larger than the molecular diameter of the therapeutic compound that control the amount and rate of drug released from a drug implant where the drug reservoir dictates the duration of therapy delivered from the drug implant
  • GS0101: Nanoporous membranes used in drug delivery devices for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy; miniature long-term drug implants utilizing proprietary implantable drug delivery technology; nanoporous membranes used for improving medication adherence in the treatment of chronic disease, in particular, metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy that control the amount and rate of drug released from a drug implant where the drug reservoir dictates the duration of therapy delivered from the drug implant for treatment of metabolic diseases, namely, diabetes, obesity or non-alcoholic steatohepatits, and psychological diseases, namely, Alzheimer's, dementia, sociopathy or psychopathy, and other diseases treated with small drug molecules; Electrotherapy medical devices for electrical nerve stimulation and recording, namely, neurostimulation devices, stimulating and recording electrode implants, visual prostheses and visual cortical implants; Cortical electrodes integrally attached to implantable cortical stimulators and other systems, namely, electrodes, stimulators, headpieces, and wearable video processors for the treatment of blindness; Surgical apparatus and instruments for the treatment of blindness; Medical apparatus and instruments for use in surgery for the treatment of blindness; Medical devices for the treatment of blindness
Case File Event Statements
  • 2/21/2024 - 4 months ago
    24 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN
  • 2/9/2024 - 4 months ago
    23 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 2/7/2024 - 4 months ago
    22 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 2/7/2024 - 4 months ago
    21 - SOU EXTENSION 1 FILED Type: EXT1
  • 2/7/2024 - 4 months ago
    20 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 8/15/2023 - 10 months ago
    19 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 6/20/2023 - a year ago
    18 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/20/2023 - a year ago
    17 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 5/31/2023 - a year ago
    16 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 5/18/2023 - a year ago
    15 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/18/2023 - a year ago
    14 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 5/18/2023 - a year ago
    13 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 5/18/2023 - a year ago
    12 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 5/18/2023 - a year ago
    11 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 5/13/2023 - a year ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/12/2023 - a year ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 5/12/2023 - a year ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/14/2023 - a year ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 2/14/2023 - a year ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/14/2023 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/13/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 8/20/2022 - a year ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 8/19/2022 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 8/1/2022 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP